Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Appointed director
Fortress Biotech, Inc. (FBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
09/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/26/2023 SC 13D/A Fortress Biotech, Inc. reports a 11.3% stake in CHECKPOINT THERAPEUTICS, INC.
08/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Amendments to Second Amended and Restated Bylaws",
"THIRD AMENDED AND RESTATED BYLAWS OF FORTRESS BIOTECH, INC. — A Delaware Corporation — THIRD AMENDED AND RESTATED BY-LAWS OF FORTRESS BIOTECH, INC. Adopted August 10, 2023 ARTICLE I OFFICES SECTION 1. Principal Office . The registered office of the corporation shall be located in such place as may be provided from time to time in the Certificate of Incorporation. SECTION 2. Other Offices . The corporation may also have offices at such other places both within and without the State of Delaware as the board of directors may from time to time determine or as the business of the corporation may require. ARTICLE II STOCKHOLDERS SECTION 1. Annual Meetings . The annual meeting of the stockholders of the corporation shall be held wholly or partially by means of remote communication or at such plac...",
"Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights"
07/06/2023 SC 13D/A Fortress Biotech, Inc. reports a 13.6% stake in CHECKPOINT THERAPEUTICS, INC.
06/16/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
05/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/15/2023 8-K Quarterly results
05/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/14/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/13/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 7.3% stake in FORTRESS BIOTECH, INC.
02/10/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
02/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 4.7% stake in Fortress Biotech Inc
01/13/2023 SC 13D/A Fortress Biotech, Inc. reports a 20.7% stake in MUSTANG BIO, INC.
01/13/2023 SC 13D/A Fortress Biotech, Inc. reports a 19.3% stake in CHECKPOINT THERAPEUTICS, INC.
01/06/2023 SC 13D/A Fortress Biotech, Inc. reports a 11.3% stake in AVENUE THERAPEUTICS, INC.
12/19/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/04/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
10/21/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/17/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy